InflaRx N.V. (IFRX)

Market Cap	91.46M
Revenue (ttm)	73,729
Net Income (ttm)	-47.05M
Shares Out	67.75M
EPS (ttm)	-0.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,490,800
Open	1.320
Previous Close	1.270
Day's Range	1.280 - 1.413
52-Week Range	0.711 - 2.815
Beta	1.46
Analysts	Strong Buy
Price Target	9.80 (+625.93%)
Earnings Date	Nov 7, 2025

About IFRX

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflamma...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 8, 2017
• Employees: 74
• Stock Exchange: NASDAQ
• Ticker Symbol: IFRX
• Website: https://www.inflarx.de

Financial Performance

In 2024, InflaRx's revenue was 165,789, an increase of 162.79% compared to the previous year's 63,089. Losses were -46.06 million, 7.96% more than in 2023.

Financial numbers in EUR

Analyst Summary

According to 5 analysts, the average rating for IFRX stock is "Strong Buy." The 12-month stock price target is $9.8, which is an increase of 625.93% from the latest price.

Price Target

$9.8

(625.93% upside)

Analyst Consensus: Strong Buy